People: Assembly Biosciences Inc (ASMB.OQ)

ASMB.OQ on NASDAQ Stock Exchange Global Select Market

19 Jul 2019
Change (% chg)

$-0.97 (-6.94%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Holubiak, Myron 

Mr. Myron Z. Holubiak is an Independent Director of Assembly Biosciences Inc, since July 2010. Mr. Holubiak is a founder and director as well as the chief executive officer of Leonard+Meron Biosciences, Inc., a privately held pharmaceutical company. Previously, Mr. Holubiak served as President of 1-800-DOCTORS, Inc. from May 2007 to January 2014. Mr. Holubiak is the former President of Roche Laboratories, Inc., USA, a major research-based pharmaceutical company, a position he held from December 1998 to August 2001. Prior to that, he held many sales and marketing positions at Roche Laboratories during his 19-year tenure there. Since September 2002, Mr. Holubiak has served on the board of directors of BioScrip, Inc., a publicly traded company and a leading home infusion provider with nationwide pharmacy and nursing capabilities, and is currently chairman of the board. From October 2012 to October 2014, Mr. Holubiak was a member of the board of directors of Intellicell Biosciences, Inc., a publicly traded regenerative medicine company. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. Mr. Holubiak received his B.S. in Molecular Biology and Biophysics from the University of Pittsburgh. Mr. Holubiak has received advanced business training from the Harvard Business School, the London School of Economics and the Centre for Health Economics at the University of York. Among other experiences, qualifications, attributes and skills, Mr. Holubiak’s extensive experience managing pharmaceutical and healthcare companies led to the conclusion of our Board that he should serve as a director of the Company in light of our business and structure.

Basic Compensation

Total Annual Compensation, USD 50,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 135,371
Fiscal Year Total, USD 185,371

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --